Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009639 citationsJournal Article

Authors

Georg Heß

Raoul Herbrecht

Jorge Romaguera · Lymphoma Research Foundation

Gregor Verhoef

Michael Crump

Christian Gisselbrecht

Abstract

Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.

Topics & Keywords

Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research Viral-associated cancers and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 27, Issue 23, pp. 3822-3829

DOI: 10.1200/jco.2008.20.7977

Field-Weighted Citation Impact: 37.12